Table 4.
Patient-reported outcomes (ITSQ score)
| ELEMENT 5 total population | India subpopulation | East Asia subpopulation | ||||
|---|---|---|---|---|---|---|
| LY IGlar N = 230 |
IGlar N = 225 |
LY IGlar N = 41 |
IGlar N = 46 |
LY IGLar N = 66 |
IGlar N = 65 |
|
| Insulin delivery device | 82.12 (1.29) | 82.01 (1.31) | 87.40 (2.51) | 85.90 (2.54) | 75.98 (3.11) | 73.25 (2.93) |
| Glycemic control | 82.14 (1.36) | 81.30 (1.38) | 89.61 (2.97) | 88.03 (3.02) | 78.93 (3.22) | 77.65 (3.05) |
| Lifestyle flexibility | 72.44 (1.77) | 70.87 (1.80) | 84.42 (6.44) | 78.95 (6.57) | 62.67 (3.75) | 61.96 (3.54) |
| Hypoglycemic control | 76.18 (1.46) | 76.52 (1.48) | 87.46 (3.01) | 86.64 (3.06) | 70.59 (3.22) | 73.75 (3.01) |
| Inconvenience of regimen | 84.75 (1.26) | 84.91 (1.28) | 87.38 (2.87) | 88.02 (2.89) | 77.26 (3.31) | 75.49 (3.10) |
| Overall score | 80.01 (1.13) | 79.76 (1.14) | 87.48 (2.51) | 86.30 (2.54) | 73.45 (2.76) | 72.74 (2.59) |
Values presented are LSM [SE] for Week 24
p > 0.05 for all comparisons between LY IGlar and IGlar in all three populations
IGlar insulin glargine (Lantus), ITSQ Insulin Treatment Satisfaction Questionnaire, LSM least-squares mean; LY IGlar Lilly insulin glargine, SE standard error